Confo Therapeutics NV
Industry
- Biotechnology
- Drug Discovery Technologies
- Large Molecule
- Antibodies
- Pharmaceuticals
Latest on Confo Therapeutics NV
Who: Eli Lilly/SiteOne Therapeutics What: Lilly has agreed to acquire privately held SiteOne and its Phase II-ready Nav1.8 inhibitor for pain for up to $1bn. Why: Pain is an area of therapeutic f
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Talaris Calls It Quits In Reverse-Merge
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. JCR Signs Deal With Sumitomo On Izcargo
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Doubles Down On Metabolic Disorde